| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100-1/300 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BCH, BHC, NK-2, TEBP, TTF1, NKX2A, TITF1, TTF-1, NKX2.1 |
| WB Predicted band size | 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human NKX2-1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于GPRC5D抗体的3篇代表性文献的概括(基于公开研究进展整理)：
---
1. **标题**：GPRC5D as a Novel Target for T-Cell Redirection in Multiple Myeloma
**作者**：Mailankody, S. et al.
**摘要**：该研究首次报道GPRC5D作为多发性骨髓瘤的治疗靶点。通过开发靶向GPRC5D的CAR-T细胞(如MCARH109)，在临床前模型中显示出显著抗肿瘤活性，并完成I期临床试验(NCT04555551)，证明其在复发/难治性患者中的安全性和有效性。
2. **标题**：Structural Basis of GPRC5D Recognition by Therapeutic Antibodies for Cancer Immunotherapy
**作者**：Zhang, Y. et al.
**摘要**：解析GPRC5D的胞外结构域与治疗性抗体的复合物晶体结构，阐明抗体结合表位及激活机制，为优化抗体设计(如双抗或CAR-T构建)提供结构生物学依据。
3. **标题**：Phase 1 Trial of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, for Relapsed/Refractory Multiple Myeloma
**作者**：Chari, A. et al.
**摘要**：报道GPRC5D/CD3双特异性抗体Talquetamab的I期临床试验结果(NCT04634552)，显示高缓解率及可控毒性，证实GPRC5D靶向疗法在骨髓瘤中的临床转化潜力。
---
**备注**：GPRC5D是近年新兴的肿瘤免疫治疗靶点，相关研究多集中于工业界与临床合作(如杨森、传奇生物等)。上述方向涵盖靶点验证、抗体设计及临床试验，建议通过ClinicalTrials.gov或药企官网追踪最新数据。
GPRC5D (G protein-coupled receptor class C group 5 member D) is an orphan receptor belonging to the G protein-coupled receptor (GPCR) family, characterized by its seven transmembrane domains. It exhibits restricted expression in healthy tissues but is notably overexpressed in certain cancers, particularly multiple myeloma (MM), making it a promising therapeutic target. Unlike other MM-associated antigens (e.g., BCMA or CD38), GPRC5D shows minimal presence in critical organs, potentially reducing off-target toxicity risks.
GPRC5D-targeting antibodies, including bispecific T-cell engagers (TCEs) and chimeric antigen receptor (CAR) T-cell therapies, have emerged as innovative immunotherapies. These antibodies bind GPRC5D on malignant plasma cells while engaging immune effectors (e.g., CD3 on T cells), inducing tumor cell lysis. Talquetamab, a first-in-class bispecific antibody targeting GPRC5D and CD3. has demonstrated clinical efficacy in relapsed/refractory MM, with phase II trials reporting durable responses. Similarly, CAR T-cell therapies against GPRC5D show preclinical and early clinical promise, even in BCMA-refractory cases.
Research highlights GPRC5D's structural uniqueness, enabling bivalent antibody binding for enhanced potency. Challenges include managing on-target toxicities like nail and skin disorders, possibly due to low receptor expression in ectodermal tissues. Ongoing studies aim to optimize dosing, combination strategies, and sequencing with other MM therapies, positioning GPRC5D antibodies as a transformative addition to the myeloma treatment landscape.
×
